Development of a prophylactic ebola vaccine using an heterologous prime-boost regimen: phase ii

  • Description
  • Details
  • Subprojects
  • History
  • Publications
  • Patents
  • Trials
Project Title: Development of a prophylactic ebola vaccine using an heterologous prime-boost regimen: phase ii
Project Number: CORDIS-209445
Project web address: Follow on CORDIS
 
Project Description:
The main objective therefore of EBOVAC 2 is to provide extensive and robust data on the safety, immunogenicity and efficacy of the Ad26.ZEBOV and MVA-BN-Filo vaccine. This will be done by: 1. Carrying out translational studies to link vaccine elicited immune responses in humans to protection from Ebola in vaccinated non-human primates (via WP4) 2. Carrying out Phase II trials in African and European volunteers in 6 countries, four in Africa and two in the EU with an overall target enrolment of approximately 1,500 subjects. Given the compressed nature of this development program, the Phase II studies will be conducted in parallel with the planned Phase III study (EBOVAC1). The phase II studies will be placebo-controlled and will be conducted in locations where it is possible to perform carefully controlled safety studies (via WP2). 3. Evaluating the use of the vaccine in special population groups, such as children (ages 1-17 years), the elderly (ages 50-65) and individuals infected with HIV, to confirm safety and immunogenicity. It is intended that Phase II trials will begin as soon as safety data are available from Phase I trials (via WP2). 4. Monitoring and characterising immune response to the proposed vaccine (via WP3). 5. Boosting the capacity of African centres, staff and infrastructure in preparation for Phase III studies and communicating and disseminating widely the results of EBOVAC2 as they becomeavailable to all key stakeholders (via WP6). 6. Contributing all data to the Central Information Repository for use by other Ebola programme projects as well as the wider community (via WP5).
 
Project Terms:
There are no related terms in database.
Project Title: Development of a prophylactic ebola vaccine using an heterologous prime-boost regimen: phase ii
Project Number: CORDIS-209445
Project web address: Follow on CORDIS
Organization: Institut National De La Sante Et De La Recherche Medicale, France, Paris
Collaborators: London Sch/Hygiene &Tropical Medicine, GB
The Chancellor, Masters And Scholars Of The University Of Oxford, GB
Centre Muraz, BF
Inserm-Transfert Sa, FR
Janssen Vaccines & Prevention B.V, NL
 
Project Categories:
Natural Sciences
Behavioral and Social Sciences
 
Other Information:
Fiscal Year: 2014
Project Start Date: 1 December 2014
Project End Date: 30 November 2019
Project program: H2020-EU.3.1.7.13.
 
Project Funding Information:
Year Funding Organization Total Funding, $
2014 European Research Council $61,360,181
Project Title: Development of a prophylactic ebola vaccine using an heterologous prime-boost regimen: phase ii
Project Number: CORDIS-209445
Project web address: Follow on CORDIS
 
Title FY Funding
There are no results for this project in database.
Project Title: Development of a prophylactic ebola vaccine using an heterologous prime-boost regimen: phase ii
Project Number: CORDIS-209445
Project web address: Follow on CORDIS
 
Project Title Organization FY Funding
Project Title: Development of a prophylactic ebola vaccine using an heterologous prime-boost regimen: phase ii
Project Number: CORDIS-209445
Project web address: Follow on CORDIS
 
Title Journal Year Country Rel
Project Title: Development of a prophylactic ebola vaccine using an heterologous prime-boost regimen: phase ii
Project Number: CORDIS-209445
Project web address: Follow on CORDIS
 
Title Year
Project Title: Development of a prophylactic ebola vaccine using an heterologous prime-boost regimen: phase ii
Project Number: CORDIS-209445
Project web address: Follow on CORDIS
 
Title Phase Year